Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Nephrol Dial Transplant ; 31(11): 1835-1845, 2016 11.
Artigo em Inglês | MEDLINE | ID: mdl-27190361

RESUMO

BACKGROUND: Treatment of iron deficiency with intravenous (i.v.) iron is a first-line strategy to improve anaemia of chronic kidney disease. Previous in vitro experiments demonstrated that different i.v. iron preparations inhibit differentiation of haematopoietic stem cells to monocytes, but their effect on monocyte differentiation to macrophages and mature dendritic cells (mDCs) has not been assessed. We investigated substance-specific effects of iron sucrose (IS), sodium ferric gluconate (SFG), ferric carboxymaltose (FCM) and iron isomaltoside 1000 (IIM) on monocytic differentiation to M1/M2 macrophages and mDCs. METHODS: Via flow cytometry and microRNA (miRNA) expression analysis, we morphologically and functionally characterized monocyte differentiation to M1/M2 macrophages and mDCs after monocyte stimulation with IS, SFG, FCM and IIM (0.133, 0.266 and 0.533 mg/mL, respectively). To assess potential clinical implications, we compared monocytic phagocytosis capacity in dialysis patients who received either 500 mg IS or IIM. RESULTS: Phenotypically, IS and SFG dysregulated the expression of macrophage (e.g. CD40, CD163) and mDC (e.g. CD1c, CD141) surface markers. Functionally, IS and SFG impaired macrophage phagocytosis capacity. Phenotypic and functional alterations were less pronounced with FCM, and virtually absent with IIM. In miRNA expression analysis of mDCs, IS dysregulated miRNAs such as miR-146b-5p and miR-155-5p, which are linked to Toll-like receptor and mitogen-activated protein kinase signalling pathways. In vivo, IS reduced monocytic phagocytosis capacity within 1 h after infusion, while IIM did not. CONCLUSIONS: This study demonstrates that less stable i.v. iron preparations specifically affect monocyte differentiation towards macrophages and mDCs.


Assuntos
Anemia Ferropriva/tratamento farmacológico , Diferenciação Celular/efeitos dos fármacos , Células Dendríticas/citologia , Compostos de Ferro/administração & dosagem , Macrófagos/citologia , Monócitos/citologia , Anemia Ferropriva/imunologia , Anemia Ferropriva/patologia , Estudos de Casos e Controles , Células Dendríticas/efeitos dos fármacos , Células Dendríticas/metabolismo , Dissacarídeos/administração & dosagem , Dissacarídeos/farmacologia , Compostos Férricos/administração & dosagem , Compostos Férricos/farmacologia , Óxido de Ferro Sacarado , Ácido Glucárico/administração & dosagem , Ácido Glucárico/farmacologia , Hematínicos/administração & dosagem , Hematínicos/farmacologia , Humanos , Injeções Intravenosas , Compostos de Ferro/farmacologia , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismo , Maltose/administração & dosagem , Maltose/análogos & derivados , Maltose/farmacologia , MicroRNAs/genética , Monócitos/efeitos dos fármacos , Monócitos/metabolismo , Fagocitose/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA